by Richard Daverman, PhD
December 31, 2012 -- Sichuan Kelun Pharma will spend $135 million to purchase a 12.3% stake in Lijun International Pharma. Both companies are involved in the IV drug market in China, though Lijun’s primary focus is on antibiotics, particularly macrolides. Lijun, which listed on the Hong Kong exchange in 2005, became involved with IV products by buying Shijiazhuang No.4 Pharma in 2007. Kelun will acquire 360 million Lijun shares from two of Lijun’s major shareholders. More details....
Stock Symbols: (SHE: 002422) (HK: 2005)
